Abraxane: Clinical Trials

39 trials of Abraxane, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

19 completed, 7 recruiting, 4 active not recruiting, 4 terminated. 39 Phase 3, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 339Completed 19, Recruiting 7, Active not recruiting 4, Terminated 4, Unknown 4, Withdrawn 1
Phase 27Active not recruiting 2, Recruiting 2, Completed 1, Unknown 1, Withdrawn 1

Follow Abraxane: new trials by email Literature Review of Abraxane trials Research Report on Abraxane

Trials (filtered) newest first · largest first

All 39 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
Biospecimen Collection, Computed Tomography, Fluorouracil - Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Phase 3RecruitingSWOG Cancer Research Network942026-05-132026-05-22
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma
Phase 2 / Phase 3Active not recruitingBristol-Myers Squibb4702025-10-232026-06-03
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure, Biospecimen Collection, Capecitabine - Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8
Phase 3RecruitingNRG Oncology3562025-08-212026-08-25
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication - Triple Negative Breast Neoplasms
Phase 3RecruitingMerck Sharp & Dohme LLC10002025-03-162026-11-10
The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer
Nab paclitaxel, Gemcitabine, Cisplatin - Pancreatic Acinar Cell Carcinoma, Pancreatic Adenocarcinoma
Phase 2 / Phase 3Active not recruitingAlliance for Clinical Trials in Oncology102024-08-132026-10-19
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Carboplatin, Computed Tomography, Magnetic Resonance Imaging - Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Phase 3RecruitingNational Cancer Institute (NCI)3042024-07-192026-11-12
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Sacituzumab tirumotecan, Doxorubicin, Paclitaxel - Endometrial Cancer
Phase 3Active not recruitingMerck Sharp & Dohme LLC7102023-12-062026-08-28
CisPlatin plUs Gemcitabine and Nabpaclitaxel (GAP) as pReoperative Chemotherapy Versus Immediate Resection in patIents With resecTable BiliarY Tract Cancers (BTC) at High Risk for Recurrence
Gemcitabine, Nab paclitaxel, Cisplatin - Biliary Tract Cancer, Cholangiocarcinoma
Phase 2 / Phase 3RecruitingGruppo Oncologico del Nord-Ovest3002023-11-072026-09-09
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
Carboplatin, Cisplatin, Computed Tomography - Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8
Phase 3RecruitingNRG Oncology4742023-07-122026-08-17
Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer
Aumolertinib monotherapy, Osimertinib monotherapy, Pemetrexed - NSCLC
Phase 3TerminatedEQRx International, Inc.82022-12-142024-05-02
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
SBP-101, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma
Phase 2 / Phase 3RecruitingPanbela Therapeutics, Inc.6002022-08-082024-11-06
Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases
Anti-CEA CAR-T cells, gemcitabine/nab paclitaxel, NLIR+FU/FA - Malignant Tumor of Pancreas Metastatic to Liver
Phase 2 / Phase 3WithdrawnSorrento Therapeutics, Inc.2021-11-012022-04-01
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)
Pembrolizumab SC, Pembrolizumab IV, Paclitaxel - Non-Small Cell Lung Cancer
Phase 3CompletedMerck Sharp & Dohme LLC5312021-08-052026-10-07
RegoNivo vs Standard of Care Chemotherapy in AGOC
Regorafenib, Nivolumab, Docetaxel - Gastro-Oesophageal Cancer
Phase 3CompletedAustralasian Gastro-Intestinal Trials Group4622021-05-052026-06-10
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Nab paclitaxel, Gemcitabine, mFOLFIRINOX - Pancreatic Adenocarcinoma
Phase 3UnknownFudan University6002021-04-012021-04-08
Precise Therapy for Refractory HER2 Positive Advanced Breast Cancer
Trastuzumab, Pertuzumab, Nab paclitaxel - HER2+ Breast Cancer
Phase 3UnknownFirst Affiliated Hospital Xi'an Jiaotong University1202021-01-012022-06-23
Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
Relacorilant, 100 mg and 25 mg, Nab-paclitaxel - Metastatic Pancreatic Ductal Adenocarcinoma
Phase 3TerminatedCorcept Therapeutics432020-06-302023-11-18
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
alpelisib, placebo, nab-paclitaxel - Triple Negative Breast Neoplasms
Phase 3TerminatedNovartis Pharmaceuticals1372020-06-082026-09-10
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer
Atezolizumab, Nab-Paclitaxel - Triple-Negative Breast Cancer
Phase 3CompletedHoffmann-La Roche1842019-12-102025-12-26
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX - Pancreatic Cancer Non-resectable
Phase 3CompletedKyntra Bio2842019-05-102024-11-05

Showing 20 of 39. Sign in to see all of them.

Conditions studied

Pancreatic Neoplasms (11)  ·  Breast Neoplasms (5)  ·  Triple Negative Breast Neoplasms (5)  ·  Adenocarcinoma (3)  ·  Carcinoma, Non-Small-Cell Lung (3)  ·  Lung Neoplasms (3)  ·  Neoplasms (3)  ·  Carcinoma, Ductal, Breast (2)  ·  Cholangiocarcinoma (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Endocrine Gland Neoplasms (2)  ·  Endocrine System Diseases (2)  ·  Neoplasms by Site (2)  ·  Pancreatic Diseases (2)

Sponsors

Celgene (4)  ·  Merck Sharp & Dohme LLC (3)  ·  Fondazione Michelangelo (2)  ·  Fudan University (2)  ·  Hoffmann-La Roche (2)  ·  NRG Oncology (2)  ·  National Cancer Institute (NCI) (2)  ·  SWOG Cancer Research Network (2)  ·  Alliance for Clinical Trials in Oncology (1)  ·  Australasian Gastro-Intestinal Trials Group (1)  ·  Bristol-Myers Squibb (1)  ·  Cellectar Biosciences, Inc. (1)  ·  Corcept Therapeutics (1)  ·  EQRx International, Inc. (1)  ·  First Affiliated Hospital Xi'an Jiaotong University (1)

Countries

United States (28)  ·  Italy (18)  ·  Spain (18)  ·  Germany (16)  ·  France (14)  ·  Australia (13)  ·  Canada (13)  ·  Austria (12)  ·  South Korea (11)  ·  United Kingdom (11)  ·  China (10)  ·  Belgium (9)  ·  Poland (9)  ·  Taiwan (9)  ·  Japan (8)

Top investigators

Luca Gianni, MD (2)  ·  Alex A. Adjei, MD, PhD (1)  ·  Arthur William Blackstock, MD (1)  ·  Benjamin Movsas, MD (1)  ·  Charles B Simone (1)  ·  Daniel Von Hoff, MD (1)  ·  Evan Hersh, MD (1)  ·  George Blumenschein, MD (1)  ·  Gregory A. Masters, MD (1)  ·  Hak Choy, MD (1)  ·  Hiroji Iwata, MD, PhD (1)  ·  Hope S Rugo (1)

Results publications

PMID 20164695, PMID 22162229, PMID 24131140, PMID 25398812, PMID 25601342, PMID 25638248, PMID 26056183, PMID 26372701, PMID 26606200, PMID 26655559, PMID 26802153, PMID 26802160, PMID 26869049, PMID 28315068, PMID 28620884, PMID 29327055, PMID 30914290, PMID 30998813, PMID 31841363, PMID 31849532, PMID 32450725, PMID 33345430, PMID 33630475, PMID 33661301, PMID 33813673, PMID 34252375, PMID 34616010, PMID 35182721, PMID 36436615, PMID 36521097, PMID 36738929, PMID 36814222, PMID 36842666, PMID 37014668, PMID 37368098, PMID 38508449, PMID 38589856, PMID 38935373, PMID 39169033, PMID 39615497, PMID 39671534, PMID 39854662, PMID 42535874, PMID 42604879

NIH funding

2023 (3), 2019 (2), U10CA180868 (2), U10CA180888 (2), 2014 (1), 2025 (1), U10CA031946 (1), U10CA180820 (1), U10CA180821 (1)